Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for Alzheimer’s disease, a new study shows.

The diabetes and weight loss drug Ozempic could lower the risk of Alzheimer’s disease among people with type 2 diabetes, according to a new study published Thursday. Alzheimer’s

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared to patients taking seven other diabetes drugs, researchers reported.

Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA considers banning compounded versions.

In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes.

According to a recent study, certain classes of weight loss drugs — including Ozempic — may have positive effects on the brain and patients with type 2 diabetes.

Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks.

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients.

Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills. The post Drug in Ozempic may also help reduce risk of Alzheimer’s appeared first on Talker.

Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of Alzheimer’s disease.